Researchers Attenuated Pathogenic Bronchitis Virus
A new study reveals a technique to weaken viruses using laboratory strains to potentially streamline vaccine production.
Updated on Oct. 9, 2026 in Life Sciences
Live Poll
Should scientists prioritize developing faster methods for agricultural vaccine production?
Researchers have successfully attenuated a pathogenic infectious bronchitis virus by replacing its spike gene with that of a laboratory strain. This modification allowed the virus to grow in cell cultures, presenting a potential alternative to traditional vaccine development methods.
Why it matters
Current vaccine production relies on a costly and time-consuming process involving over 80 passages through embryonated eggs. By enabling virus growth in Vero cell lines, this method could facilitate faster vaccine adaptation and reduce industry dependence on disease-free eggs.
The study utilized reverse genetics to replace the spike gene of the D388 strain with the Beaudette spike gene. The resulting attenuated virus remained genetically stable while triggering a controlled innate immune response in chickens.
The players
The Pirbright Institute
The Pirbright Institute is a world-leading research center focused on the study and control of viral diseases in livestock.
Journal of Virology
The Journal of Virology is a peer-reviewed scientific journal published by the American Society for Microbiology that covers all aspects of virology.
The details
The modified virus demonstrated efficient growth in Vero cell lines, allowing researchers to bypass the need for embryonated hen's eggs. Furthermore, the attenuated virus produced significantly fewer clinical signs of disease in test subjects compared to the original strain.
Timeline
October 9, 2026: The study was published in the Journal of Virology.
The Big Picture
This discovery shifts the trajectory of veterinary virology by demonstrating that modified spike proteins can successfully replace legacy propagation techniques. This breakthrough challenges the long-standing reliance on embryonated eggs, potentially enabling a new paradigm of rapid, cell-based vaccine manufacturing.
While this study focuses on veterinary applications, the move toward cell-based vaccine production could eventually lead to more stable and faster-produced vaccines for various agricultural sectors. This innovation aims to reduce supply chain bottlenecks in the production of animal health products.
The takeaway
This study demonstrates that genetic modification can successfully replicate the biological requirements for vaccine development in a controlled environment. Moving away from biological inputs like eggs could significantly stabilize the production of vital animal vaccines in the future.
Further reading
For more information on current breakthroughs in animal disease research, visit our Life Sciences section.
Source note: This article includes information reported by Foodagribusiness.
Live Poll
Should scientists prioritize developing faster methods for agricultural vaccine production?
